BACKGROUND: Neoadjuvant chemoradiotion therapy (CRT) for advanced rectal cancer has improved local disease. Complete rectal wall tumor regression may be associated with the absence of viable cancer cells in the mesorectum, and thus local excision (LE) of such lesions as an alternative to radical surgery has recently gained interest. We report the long-term outcome of LE in patients with a mural pathological complete response (ypT0) after CRT. METHODS: A retrospective review of patients with rectal cancer treated by CRT and followed by LE with pathological complete response in the specimen between 1998 and 2009 was performed. RESULTS: A total of 174 patients had neoadjuvant CRT, and 68 (39 %) showed complete clinical response (cCR). Thirty-one of the cCR patients underwent LE; 23 of them resulted in ypT0 and 8 had residual disease. The ypT0 group included 12 men and 11 women with a median age of 66. The pretreatment stage was T3N1 in 4 (17 %) patients, T3N0 in 11 (48 %), T2N1 in 3 (13 %), and T2N0 in 5 (22 %). The median tumor distance from the anal verge was 6 cm. Sixteen patients (70 %) underwent transanal excision, and 7 (30 %) were treated by transanal-endoscopic microsurgery. Three patients died: one of pneumonia, one of melanoma of the rectum, and one of lung carcinoma. No local or distant recurrences were detected in the remaining 20 patients. The median follow-up was 87 months. CONCLUSIONS: Although radical rectal resection is the treatment of choice, LE of complete rectal tumor regression could be a safe alternative with an acceptable result in selected patients.
BACKGROUND: Neoadjuvant chemoradiotion therapy (CRT) for advanced rectal cancer has improved local disease. Complete rectal wall tumor regression may be associated with the absence of viable cancer cells in the mesorectum, and thus local excision (LE) of such lesions as an alternative to radical surgery has recently gained interest. We report the long-term outcome of LE in patients with a mural pathological complete response (ypT0) after CRT. METHODS: A retrospective review of patients with rectal cancer treated by CRT and followed by LE with pathological complete response in the specimen between 1998 and 2009 was performed. RESULTS: A total of 174 patients had neoadjuvant CRT, and 68 (39 %) showed complete clinical response (cCR). Thirty-one of the cCR patients underwent LE; 23 of them resulted in ypT0 and 8 had residual disease. The ypT0 group included 12 men and 11 women with a median age of 66. The pretreatment stage was T3N1 in 4 (17 %) patients, T3N0 in 11 (48 %), T2N1 in 3 (13 %), and T2N0 in 5 (22 %). The median tumor distance from the anal verge was 6 cm. Sixteen patients (70 %) underwent transanal excision, and 7 (30 %) were treated by transanal-endoscopic microsurgery. Three patients died: one of pneumonia, one of melanoma of the rectum, and one of lung carcinoma. No local or distant recurrences were detected in the remaining 20 patients. The median follow-up was 87 months. CONCLUSIONS: Although radical rectal resection is the treatment of choice, LE of complete rectal tumor regression could be a safe alternative with an acceptable result in selected patients.
Authors: Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-11 Impact factor: 7.038
Authors: B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: David B Chessin; Warren Enker; Alfred M Cohen; Philip B Paty; Martin R Weiser; Leonard Saltz; Bruce D Minsky; W Douglas Wong; Jose G Guillem Journal: J Am Coll Surg Date: 2005-06 Impact factor: 6.113
Authors: C J Kim; T J Yeatman; D Coppola; A Trotti; B Williams; J S Barthel; W Dinwoodie; R C Karl; J Marcet Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: Glenda G Callender; Prajnan Das; Miguel A Rodriguez-Bigas; John M Skibber; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Barry W Feig Journal: Ann Surg Oncol Date: 2009-10-22 Impact factor: 5.344
Authors: G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche Journal: Surg Endosc Date: 2007-10-18 Impact factor: 4.584
Authors: Isabelle Bedrosian; Miguel A Rodriguez-Bigas; Barry Feig; Kelly K Hunt; Lee Ellis; Steven A Curley; Jean Nicolas Vauthey; Marc Delclos; Christopher Crane; Nora Janjan; John M Skibber Journal: J Gastrointest Surg Date: 2004-01 Impact factor: 3.452
Authors: Avery S Walker; Nathan P Zwintscher; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele Journal: J Cancer Date: 2014-01-05 Impact factor: 4.207
Authors: Kyung Su Han; Dae Kyung Sohn; Dae Yong Kim; Byung Chang Kim; Chang Won Hong; Hee Jin Chang; Sun Young Kim; Ji Yeon Baek; Sung Chan Park; Min Ju Kim; Jae Hwan Oh Journal: Cancer Res Treat Date: 2015-09-22 Impact factor: 4.679
Authors: Liliana Bordeianou; Lillias Holmes Maguire; Karim Alavi; Ranjan Sudan; Paul E Wise; Andreas M Kaiser Journal: J Gastrointest Surg Date: 2014-05-13 Impact factor: 3.452